Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | MMP13 | P45452 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437183 | 0.94 | GAA (0.61) | GAATSHRMMP13LMNAALDH1A1 | |
| SCHEMBL21222741 | 0.94 | GAA (0.61) | GAATSHRMMP13LMNAALDH1A1 | |
| SCHEMBL13947589 | 0.89 | LMNA (0.78) | GAATSHRMMP13LMNAALDH1A1 | |
| SCHEMBL13102334 | 0.87 | MMP13 (0.85) | GAATSHRMMP13LMNAALDH1A1 | |
| SCHEMBL29437161 | 0.87 | MMP13 (0.85) | GAATSHRMMP13LMNAALDH1A1 | |
| SCHEMBL12330697 | 0.86 | CA2 (0.62) | GAATSHRMMP13LMNAALDH1A1 | |
| SCHEMBL19623369 | 0.83 | ALDH1A1 (0.78) | GAATSHRMMP13LMNAALDH1A1 | |
| SCHEMBL7082686 | 0.83 | TSHR (0.73) | GAATSHRMMP13LMNAALDH1A1 | |
| SCHEMBL21246550 | 0.83 | LMNA (0.61) | TSHRMMP13LMNAALDH1A1HTT | |
| SCHEMBL28717596 | 0.83 | MMP13 (0.57) | GAATSHRMMP13LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11112654-B2 | Liquid crystal display device | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2021-09-07 | — | — | US | disclosed |
| WO-2019189632-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-9976086-B2 | Liquid crystal aligning agent containing polyimide precursor having thermally-leaving group and/or polyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20160264867-A1 | LIQUID CRYSTAL ALIGNING AGENT CONTAINING POLYIMIDE PRECURSOR HAVING THERMALLY-LEAVING GROUP AND/OR POLYIMIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160244673-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | GAA 1045/4885TSHR 1346/4885MMP13 2590/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | GAA 181/4885TSHR 4634/4885MMP13 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.